-
Innovation Ranking
Innovation Ranking – Novavax Inc
Novavax Inc (Novavax) is a biotechnology company that discovers, develops and commercializes vaccines to prevent a wide range of infectious diseases. The company develops genetically-engineered vaccine candidates harnessing three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Its pipeline products include NVX-CoV2373 for coronavirus, NanoFlu for seasonal influenza, ResVax for respiratory syncytial syndrome and vaccines indicated for the prevention of Ebola virus, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). It is also developing proprietary immune stimulating...
-
Product Insights
NewNet Present Value Model: Bristol-Myers Squibb Co’s Afimetoran
Empower your strategies with our Net Present Value Model: Bristol-Myers Squibb Co's Afimetoran report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Novavax Inc’s NanoFlu
Empower your strategies with our Net Present Value Model: Novavax Inc's NanoFlu report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewRespiratory Syncytial Virus (RSV) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2024" provides an overview of Respiratory Syncytial Virus (RSV) Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Respiratory Syncytial Virus (RSV) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Seasonal Influenza Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Seasonal Influenza Clinical Trial Report Overview A total of 310 seasonal influenza clinical trials were conducted as of February 2024. The Seasonal Influenza clinical trial report provides a comprehensive understanding of the seasonal influenza clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · North America · ...
-
Company Insights
Innovation and Patenting activity of Novavax Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Novavax Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QNIV in Influenza A Virus, H1N1 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QNIV in Influenza A Virus, H1N1 Subtype Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. QNIV in Influenza A Virus, H1N1 Subtype Infections...
-
Product Insights
NewInfluenza A Virus, H5N1 Subtype Infections – Drugs In Development, 2024
Empower your strategies with our Influenza A Virus, H5N1 Subtype Infections – Drugs In Development, 2024 report and make more profitable business decisions. H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain, and diarrhea. Predisposing factors include working with poultry, touching an infected bird, and eating raw or undercooked poultry...
-
Product Insights
NewSeasonal Influenza – Drugs In Development, 2024
Empower your strategies with our Seasonal Influenza – Drugs In Development, 2024 report and make more profitable business decisions. Seasonal influenza, commonly referred to as "the flu", is a contagious respiratory illness caused by influenza viruses. It typically occurs in outbreaks during the fall and winter months, peaking between December and February in the Northern Hemisphere. The flu can cause mild to severe illness and, in some cases, can lead to hospitalization or even death, especially among vulnerable populations. Symptoms of...
-
Product Insights
NewSevere Acute Respiratory Syndrome (SARS) – Drugs In Development, 2024
Empower your strategies with our Severe Acute Respiratory Syndrome (SARS) – Drugs In Development, 2024 report and make more profitable business decisions. Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea, and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS. The Severe Acute Respiratory Syndrome (SARS) drugs in development...